GeoVax Labs, Inc.
3:45 PM - 4:00 PM (EST), Tuesday, February 7, 2023 ・ Winter Garden
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompr
Ticker:
GOVX
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Georgia
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Immunology
Lead Product in Development:
GEO-CM04S1 (COVID-19 vaccine)
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
